Christopher Thomas Giordano - 17 May 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
CEO, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
17 May 2024
Net transactions value
$0
Form type
4
Filing time
21 May 2024, 17:00:50 UTC
Previous filing
10 Jun 2022
Next filing
12 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +437 $0.000000 437 17 May 2024 Common Stock 437 $3.55 Direct F1
holding TENX Stock Option (right to buy) 125 17 May 2024 Common Stock 125 $992.00 Direct F2, F3
holding TENX Stock Option (right to buy) 157 17 May 2024 Common Stock 157 $3152.00 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
F2 These options were previously reported as covering 200,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
F3 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F4 These options were previously reported as covering 250,000 shares at an exercise price of $1.97 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
F5 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.